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1 These two authors have contributed equally to thiThe present study demonstrates that theaﬂavins exploit p53 to impede metastasis in human breast
cancer cells. Our data suggest that p53-dependent reactive oxygen species (ROS) induce p53-phos-
phorylation via p38MAPK in a feedback loop to inhibit IjBa-phosphorylation and NF-jB/p65 nuclear
translocation, thereby down-regulating the metastatic proteins metalloproteinase (MMP)-2 and
MMP-9. When wild-type p53-expressing MCF-7 cells are transfected with p53 short-interfering
RNA, or treated with a pharmacological inhibitor of ROS, theaﬂavins fail to inhibit NF-jB-mediated
cell migration. On the other hand, NF-jB over-expression bestows MCF-7 cells with resistance to the
anti-migratory effect of theaﬂavins. These results indicate that inhibition of NF-jB via p53–ROS
crosstalk is a pre-requisite for theaﬂavins to accomplish the anti-migratory effect in breast cancer
cells.
Structured summary:
MINT-7295816: p53 (uniprotkb:P04637) physically interacts (MI:0915) with IKK beta (uniprotkb:O14920)
by anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Metastasis is the most frequent cause of death in patients with
advanced breast cancer and still poses a challenge to successful
cancer therapeutics, inhibiting which may provide more effective
treatment for patients with advanced breast malignancy.
Recently, use of phytochemicals to impede cancer metastasis by
addressing multiple targets that regulate the migratory capacity of
cancer cells, has gained immense importance. In this regard, theaf-
lavins, the bioactive ﬂavonoids of black tea, have been demon-
strated to induce apoptosis and to inhibit tumor cell invasion in
a variety of cancer cells [1,2]. However, the underlying mecha-
nisms responsible for the anti-migratory effects of theaﬂavins in
breast cancer are largely unknown.
It is acknowledged that in addition to its pro-apoptotic func-




s paper.tion of migration [3] and p53 mutation triggers the metastatic
potential in breast cancers [3]. Convincing evidence suggests that
p53 executes its function via reactive oxygen species (ROS) gener-
ation [4]. It has been reported that ROS inhibit metastasis of human
breast cancer [5] and removal of oxygen radicals by anti-oxidant
drugs impedes tumor-suppressing effect of p53 [4]. In fact, ROS
function as signaling molecules in upstream by triggering p53-acti-
vation through post-transcriptional modiﬁcation like phosphoryla-
tion [6] and in the down-stream by leading to apoptosis after being
generated via p53-induced redox active genes [7,8]. Therefore, ap-
proaches employing therapeutic agents that generate ROS in tumor
cells could signiﬁcantly enhance the therapeutic gain.
Increasing evidence suggests that NF-jB-associated pathways
are deregulated in numerous malignancies, including breast can-
cer [9,10]. The transcription factor NF-jB has been observed to
promote endothelial cell motility while RNAi suppression of
NF-jB inhibited bladder cancer cell migration [11]. Inhibition
of NF-jB activity signiﬁcantly reduced proliferation and invasion
of Hep3B cells as well as down-regulated the expression of inva-
sion-related molecules including metalloproteinase (MMP)-2 and
MMP-9 [12]. Recent studies demonstrate the signiﬁcance of p53
in regulating NF-jB-activation through different mechanisms
[13]. Data also illustrate that sustained oxidative stress maylsevier B.V. All rights reserved.
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vation by impeding the degradation of IjBa [14]. Although an
inter-relationship among enhancement of p53, increment in
ROS and inhibition in NF-jB that led to cancer cell apoptosis,
has been demonstrated [15], to date hardly any information ex-
its about the cross-talk, if any, between p53, ROS and NF-jB in
relation to retardation of human breast cancer cell migration by
plant polyphenols, theaﬂavins.
The present study describes that theaﬂavins retarded human
breast cancer cell migration by inhibiting NF-jB/p65 via p53–
ROS feed back loop. In fact, p53-dependent up-regulation of pro-
line oxidase and down-regulation of manganese superoxide dis-
mutase (MnSOD) resulted in generation of ROS that in turn
phosphorylated and activated p53 in a redox-regulatory loop via
p38MAPK to block NF-jB/p65 nuclear translocation by inhibiting
IjBa-phosphorylation. Inhibition of NF-jB in turn caused down-
regulation of pro-migratory enzymes MMP-2 and MMP-9. While
transfection of p53-short-interfering RNA (siRNA) protected wild-
type p53 (Wt-p53)-expressing MCF-7 cells from the anti-migratory
effect of theaﬂavins, over-expression of Wt-p53 sensitized mutant
p53-expressing MDA-MB-231 cells to theaﬂavin-insult, thereby
conﬁrming the contribution of p53. Furthermore, inhibition of
ROS or transient over-expression of NF-jB rendered MCF-7 cells
resistant to theaﬂavin-insult. Altogether, these results elucidate
an important role for theaﬂavins in suppressing breast cancer
metastasis by activating p53/ROS/p38MAPK positive feed back
loop that hindered NF-jB activation to ﬁnally inhibit pro-migra-
tory enzymes MMP-2 and MMP-9.
2. Materials and methods
2.1. Cell culture and treatments
Human breast carcinoma cells (MCF-7, ZR-75-1, MDA-MB-231)
were obtained from NCCS, India. The MDAH041 post-crisis skin
ﬁbroblast cell line was derived from a patient with Li-Fraumeni
syndrome. Cells were routinely maintained in complete DMEM in
a humidiﬁed CO2 incubator [1].
Cells were treated with 10 lg/ml theaﬂavins (Sigma, USA) for
12 h, unless stated otherwise, to examine its anti-migratory effect.
To assess the role of ROS and p38MAPK, MCF-7 cells were treated
with ROS scavenger N-acetyl-cysteine (NAC) (Sigma, USA) for 1 h
or p38MAPK inhibitor (SB 203580, 10 lM) (Calbiochem) for
90 min prior to incubation with theaﬂavins.
2.2. Wound healing assay
Cell migration was determined by means of unidirectional
wound healing assay as described [16]. Brieﬂy, cells were grown
to conﬂuency in 12 well plates after which a sterile blade was used
to scratch the monolayer of cells to form a unidirectional wound.
Migration was quantitated by a semi-automated, computer-as-
sisted procedure by a person blinded with respect to the experi-
mental treatment. The data from triplicate wells were calculated
as the means ± S.E.M., the migration rate of control cells was taken
as 100% and healing rate of other plates were compared with con-
trol cells.
2.3. Assessment of ROS
Cells were incubated for 20 min at 37 C in the dark with 10 lM
of dichloroﬂuorescin diacetate (DCFH-DA). DCF ﬂuorescence was
measured ﬂowcytometrically (Beckton Dickinson FACScan) and
subjected to analysis using Cell Quest 3.2 (Beckton Dickinson) soft-
ware. The probe was excited at 488 nm and emission was mea-
sured through a 530 nm band-pass ﬁlter. For confocal microscopya Leica ﬂuorescent microscope DM 900 was used to visualize the
images of cells treated with theaﬂavins and stained with DCFH-
DA. Digital images were captured with a cool (25 C) charged
coupled device (CCD) camera (Princeton Instruments) controlled
with the MetaMorph software.
2.4. Western blot analysis and coimmunoprecipitation
To assess the involvement of different proteins, whole cell ly-
sates as well as cytosolic and nuclear fractions were prepared
and ran on SDS–PAGE gels, transferred to nitrocellulose mem-
branes, as described previously [17,18], and probed with speciﬁc
antibodies, e.g., anti-p53, p65 (RelA), IjBa, phospho-IjBa (p-IkBa),
IKKb, phospho-Ser15-p53 (p-Ser15-p53), MnSOD, proline oxidase,
MMP-2 and MMP-9, procured from Santa Cruz. For the determina-
tion of direct interaction between p-Ser15-p53 and p65 or IKKb, p-
Ser15-p53 immunocomplexes from cytosol were puriﬁed using
anti-p-Ser15-p53 antibody and protein A-Sepharose beads. The
immunopuriﬁed proteins were immunoblotted with anti-p65 or
anti-IKKb. The protein of interest was visualized by chemi-lumi-
nescence. Equivalent protein loading in nuclear and cytosolic frac-
tions was veriﬁed using anti-histone H1 and anti-a-actin
antibodies (Santa Cruz), respectively.
2.5. Plasmids, siRNA and transfections
Wt-p53 was transfected in MDA-MB-231 cells through an
adenoviral vector expression system expressing Wt-p53 under
the control of cytomegalovirus promoter (Clontech). The cDNA
encoding p65 subunit of human NF-jB was subcloned into the
pcDNA3.1 vector (Invitrogen, Carlsbad, CA). The resulting p65-
pcDNA3.1 plasmids (4 lg each/million cells) were introduced sep-
arately into MCF-7 cells using LipofectAmine 2000 (Invitrogen).
Stably expressing clones were isolated by limiting dilution and
selection with G418 sulphate (Cellgro) at a concentration of
1 lg/ml and cells surviving this treatment were cloned and
screened by Western blot analysis with speciﬁc antibodies. MCF-
7 cells were transfected separately with p53-/control-ds-siRNA
and p65-/control-ds-siRNA (Santa Cruz) using LipofectAmine. The
levels of p53 and p65 expression in selected clones were estimated
by Western blotting.
2.6. Statistics
Values are shown as standard error of mean (S.E.M.), except
otherwise indicated. Data were analyzed and when appropriate,
signiﬁcance of the differences between mean values was deter-
mined by Student’s t-test. Results were considered signiﬁcant at
P < 0.05.
3. Results
3.1. Theaﬂavins inhibit migration of mammary epithelial carcinoma
cells expressing Wt-p53
Theaﬂavins have been found to successfully inhibit migration
of Wt-p53 containing MCF-7 cells in a dose-dependent manner
(Fig. 1A). However, since doses above 12.5 lg/ml of theaﬂavins
are apoptogenic in breast cancer cells, as evident from our previ-
ous studies [1], further experiments were restricted to sub-apop-
totic dose of 10 lg/ml. Interestingly, under these conditions,
theaﬂavins failed to furnish any signiﬁcant effect in mutant
p53-containing MDA-MB-231 cells (Fig. 1B). These results led us
to hypothesize that anti-migratory effects of theaﬂavins might
be favoured in Wt-p53-expressing mammary epithelial carcinoma
cells.
Fig. 1. Theaﬂavins retard migration of human breast cancer cells with Wt-p53. Human breast cancer cells, (A) MCF-7 and (B) MDA-MB-231, were treated with different doses
of theaﬂavins for 12 h and cell migration was represented graphically. The migration rate of control cells was considered to be 100% and healing rate of treated sets was
relative of control cells. The data were representative of triplicate experiments and calculated as the means ± S.E.M. (C) To verify the role of p53 in cell migration, MCF-7, ZR-
75-1, MDAH041 and MDA-MB-231 cells were treated with 10 lg/ml theaﬂavins and percentage inhibition of invasive potential were compared. (D) Expression level of p53 in
lysates of control and theaﬂavin-treated MCF-7, ZR-75-1, MDAH041 and MDA-MB-231 cells were determined by Western blot. a-Actin was used as internal loading control.
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lines with varying p53 status, e.g., Wt-p53-expressing MCF-7 and
ZR-75-1 cells, p53-null MDAH041 cells, and p53-mutated MDA-
MB-231 cells were tested for theaﬂavin-dependent inhibition in
migration (Fig. 1C). Interestingly, theaﬂavins signiﬁcantly inhib-
ited migration of Wt-p53-expressing cells, while in p53-mutated
or p53-null cells, theaﬂavins failed to resist migration (Fig. 1C)
although these phytochemicals enhanced p53 expression not only
in MCF-7 and ZR-75-1 cells but also in MDA-MB-231 cells
(Fig. 1D). These results further indicate the contribution of Wt-
p53 in theaﬂavin-induced retardation of human breast cancer cell
migration.
3.2. Retardation of breast cancer cell migration by theaﬂavins is p53-
dependent
Next, in an attempt to conﬁrm the involvement of Wt-p53, we
undertook two approaches. In the ﬁrst approach, p53-silencing in
MCF-7 (Fig. 2B, inset) prior to theaﬂavin-treatment signiﬁcantly re-
duced inhibition of migration from 70% to only 10% (Fig. 2A and B).
Secondly, over-expression of Wt-p53 in MDA-MB-231 cells
(Fig. 2D, inset), initially resistant to theaﬂavins, resulted in 60%
inhibition of migration (Fig. 2C and D). These data conﬁrm the role
of Wt-p53 in materializing the anti-migratory effect of theaﬂavins
in human breast cancer cells.3.3. Theaﬂavins induce ROS by altering the balance between pro- and
anti-oxidant enzymes in p53-expressing breast cancer cells to assert
anti-migratory effect
Interestingly, theaﬂavins induced an increase in ROS in MCF-7
cells (Fig. 3A), but not in MDA-MB-231 cells (Fig. 3B). Failure of
theaﬂavins to increase ROS in p53-knock-out MCF-7 cells
(Fig. 3C, left panel) further indicated the dependence of ROS on
p53. Our hypothesis was conﬁrmed by the generation of ROS in
Wt-p53-transfected MDA-MB-231 cells upon theaﬂavin-treatment
(Fig. 3C, right panel). A deeper insight into the mechanism of p53-
dependent ROS generation revealed that while theaﬂavins in-
creased pro-oxidant proline oxidase and decreased anti-oxidant
MnSOD in Wt-p53 MCF-7 cells, in mutant p53-containing
MDAMB-231 cells as well as in p53-knock-out MCF-7 cells no such
change was observed (Fig. 3D). These results clearly suggest that
theaﬂavins altered the balance between pro- and anti-oxidant en-
zymes in p53-dependent manner to generate ROS in MCF-7 cells
(Fig. 3D).
3.4. Theaﬂavins turn on ap53–ROS–p38MAPK–p53 loop to assert anti-
migratory effect in functional-p53-expressing breast cancer cells
Since recent reports suggested the requirement of p53-phos-
phorylation in ROS generation (6), we next veriﬁed if such
Fig. 2. Theaﬂavin-induced inhibition of breast cancer cell migration is dependent on p53. The anti-migratory effect of 10 lg/ml theaﬂavins was studied in MCF-7 cells (A and
B) transfected with p53-siRNA (B, inset), and MDA-MB-231 cells (C and D) transfected with Wt-p53 (D, inset) by unidirectional wound healing assay. Results depicted as
phase contrast images (A and C) and graphical representation (B and D), showed that Wt-p53 was indeed essential for theaﬂavins to inhibit breast cancer invasiveness. The
data from triplicate wells were calculated as the means ± S.E.M., the migration rate of control cells was taken as 100% and healing rate of other plates were compared with
control cells.
10 A. Adhikary et al. / FEBS Letters 584 (2010) 7–14post-translational modiﬁcation of p53 was required for theaﬂa-
vin-induced ROS generation. Our data illustrated that theaﬂavins
induced p53-phosphorylation at Ser15 residue (Fig. 3E) and the
effect was abrogated by p38MAPK inhibitor, SB203580
(Fig. 3E). In the presence of SB203580, theaﬂavins also failed
to generate ROS (Fig. 3E) thereby conﬁrming that p53-phosphor-
ylation via p38MAPK was indeed required for ROS production.
Interestingly, although NAC, the pharmacological inhibitor of
ROS (Fig. 3F, left panel), failed to affect theaﬂavin-induced up-
regulation of p53 in MCF-7 cells (Fig. 3F, middle panel), NAC de-
creased phospho-p38MAPK (p-p38MAPK) as well as p-Ser15-p53
(Fig. 3F, right panel). All these results together point towards the
existence of a p53–ROS–p38MAPK–p53 loop, since inhibition of
any of these factors blocked activation of others and signiﬁcantly
abolished the anti-migratory effect of theaﬂavins (Fig. 3G).3.5. Theaﬂavins retard cell migration by inhibiting NF-jB
translocation to nucleus
Since NF-jB plays a vital role in cell motility, we next explored
the involvement of this transcription factor in theaﬂavin-induced
anti-migratory cascade. In fact, theaﬂavin-treatment inhibited
recruitment of NF-jB/p65 to the nucleus of MCF-7 cells
(Fig. 4A). Moreover, transfection of NF-jB cDNA to MCF-7 cells
(Fig. 4B, inset) made them resistant to theaﬂavins (Fig. 4B). In
parallel experiment, when MCF-7 cells were transfected with
NF-jB-siRNA (Fig. 4C, inset), invasiveness was signiﬁcantly re-
duced (Fig. 4C) and theaﬂavins failed to furnish any further effect
(Fig. 4C). These results together conﬁrm that theaﬂavins retard
Wt-p53-containing human breast cancer cell migration by inhib-
iting NF-jB.
Fig. 3. Theaﬂavin-induced ROS inhibits metastasis in breast cancer with Wt-p53. MCF-7 (A, ﬂowcytometric analysis (left panel) and confocal imaging (right panels, image of
12 h incubation) and MDA-MB-231 (B, ﬂowcytometric analysis) cells were exposed to 10 lg/ml theaﬂavins over the course of 12 h, and at various time points cells were
treated with 10 lM DCFH-DA for 20 min to assess ROS production as measured by the increase in DCFDA ﬂuorescence over medium controls. To understand p53–ROS cross-
talk, (C) ROS was determined in p53-siRNA transfected MCF-7 cells (left panel) and Wt-p53 over-expressed MDAMB-231 cells (right panel). (D) Theaﬂavins increased proline
oxidase and decreased MnSOD in MCF-7 cells, whereas in MDAMB-231 and p53-knockout MCF-7 cells no such effect was observed. (E) Western blot analysis of p-p38MAPK
and p-Ser15-p53 (left panel) and ﬂow cytometric analysis of theaﬂavin-induced ROS generation (right panel) with/without p38MAPK inhibitor SB 203580. (F) Flow
cytometric data of ROS (left panel), Western blot data on the expression of p53 (middle panel), p-p38MAPK and p-Ser15-p53 (right panel) in MCF-7 cells with/without NAC
(right panel). (G) To ﬁnally conﬁrm p53–ROS–p38MAPK–p53 loop in breast cancer metastasis, migration of theaﬂavin-treated MCF-7 cells was quantiﬁed after blocking the
loop at various points. The data from triplicate wells were calculated as the means ± S.E.M., the migration rate of control cells was taken as 100% and healing rate of other
plates were compared with control cells.
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Fig. 4. Theaﬂavins impede cell migration by inhibiting nuclear translocation of NF-jB. (A) Western blot analysis of nuclear and cytosolic NF-jB protein in
control and theaﬂavin-treated MCF-7. To verify the role of NF-jB in cell migration, MCF-7 cells were transfected with NF-jB cDNA (B, inset) or with NF-jB-
siRNA (C, inset) and after theaﬂavins-treatment cell migration was determined (B and C) as mentioned previously. Values are means ± S.E.M. of triplicate
experiments. (D) Western blot analysis of NF-jB expression in p53-siRNA-transfected (upper panel) and NAC-pre-treated (lower panel) MCF-7 cells. (E) p-
Ser15-p53-associated IKKb, but not NF-jB, was detected in cytosol by Western blot analysis from the anti-p-Ser15-p53-puriﬁed immune-complex (upper
panel). Phosphorylation status of IjBa protein was determined in theaﬂavin-treated MCF-7 cell cytosol by Western blot analysis (lower panel). (F) The
expression levels of MMP-2 and MMP-9 were assessed by Western blot analysis in p53-siRNA-transfected (ﬁrst panel), NAC-pre-treated (second panel), NF-
jB-siRNA-transfected (third panel) and NF-jB-cDNA-transfected (fourth panel) MCF-7 cells.
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Fig. 5. Theaﬂavin-induced inhibition of breast cancer cell migration via p53/ROS/
p38MAPK loop of ampliﬁcation.
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inhibiting IjBa-phosphorylation
Our results illustrate that in MCF-7 cells transfected with
p53-siRNA, theaﬂavins failed to inhibit nuclear translocation of
NF-jB (Fig. 4D, upper panel). Similar results were obtained
when MCF-7 cells were pre-treated with ROS quencher, NAC
(Fig. 4D, lower panel). These results validated the hypothesis
that activation of p53–ROS loop was pre-requisite for theaﬂavins
to inhibit NF-jB. An effort to understand the mechanism of p53-
mediated NF-jB activation failed to disclose any physical associ-
ation between p-Ser15-p53 and NF-jB (Fig. 4E, upper panel).
However, co-immunoprecipitation studies exhibited a direct
interaction of p-Ser15-p53 with IKKb (Fig. 4E, upper panel)
thereby inhibiting IjBa-phosphorylation (Fig. 4E, lower panel)
that ﬁnally hindered NF-jB nuclear translocation (Fig. 4D).
These ﬁndings clearly explain how p53 controls NF-jB in thea-
ﬂavin-treated MCF-7 cells.
3.7. NF-jB inhibition causes down-regulation of metastatic proteins
MMP-2 and MMP-9
Finally, theaﬂavin-treatment signiﬁcant reduced the protein
levels of MMP-2 and MMP-9 in MCF-7 (Fig. 4F). Transfection of
MCF-7 with p53-siRNA or treatment with NAC resisted such
down-regulation by theaﬂavins (Fig. 4F). Interestingly, while NF-
jB-siRNA reduced MMP-2 and MMP-9, NF-jB over-expression
augmented the same with no further effect of theaﬂavins
(Fig. 4F). These results therefore signify that p53–ROS-mediated
inhibition of NF-jB recruitment to nucleus by theaﬂavins down-
regulated pro-migratory proteins MMP-2 and MMP-9 thereby
resulting in retardation of cell migration.
4. Discussion
A deep understanding of molecular events during tumor metas-
tasis and migration-related cascade components can offer poten-
tial therapeutic strategies for intervening tumor metastasis. In
this regard, phytochemicals being immunoprotective [19–21] are
considered safe for their optimal usage as anti-cancer candidates
[1,22,23]. However, their potency as anti-migratory agents for
invasive cancers yet anticipates disclosure.
Our work exposed the anti-migratory nature of theaﬂavins,
which targeted Wt-p53 for ﬁne-tuning of NF-jB-mediated metas-
tasis in human breast cancer cells. This is in accordance with ear-
lier reports where induction of Wt-p53 retarded the invasive
potential of breast cancer cells [24]. Also, evidence suggests that
the anti-migratory effect of several drugs is inﬂuenced by their
capacity to generate ROS in tumor cells [25]. A clear connection be-
tween p53 and ROS generation, where over-expression of Wt-p53
leads to elevation in pro-oxidant enzymes, including two ROS gen-
erating enzymes quinone oxidoreductase and proline oxidase, has
been established earlier [7]. More candidates have been added to
the list of p53-induced pro-oxidant genes, which include BAX,
PUMA and p66Shc [26,27]. Suppression of anti-oxidant gene
MnSOD by p53-activation or over-expression is an alternative
way to increase cellular ROS, conferring oxidative stress [28]. In
MCF-7 cells, by creating a pro-oxidant milieu, theaﬂavins ensured
the generation of ROS.
Since both ROS and p53 participate in multiple cellular pro-
cesses including cancer metastasis [29], there might be interac-
tions between ROS and p53 and intersections between their
signaling pathways. The inter-relationship between ROS levels,
DNA damage accumulation and p53-activation in relation to cell
death has already been acknowledged [30]. In fact, among diverse
covalent post-translational modiﬁcations of p53, phosphorylation,methylation and acetylation generally lead to its stabilization,
accumulation and activation [29]. Recent reports have implicated
ROS in the phosphorylation of p53, mediated by protein kinases
including p38MAPK, which, depending on the cellular context
and stimuli, can phosphorylate p53 in Ser15 residue [6,31]. How-
ever, the contribution of p53–ROS cross-talk in regulating cancer
cell migration remains enigmatic. We observed that theaﬂavins
targeted p53 for generating ROS that in turn induced p38MAPK-
mediated p53-phosphorylation at Ser15, which further contributed
to enhanced ROS production. Our results thus conﬁrmed the exis-
tence of p53–ROS–p53 feed back loop that restrained breast cancer
cell motility.
The concept of p53 being involved in regulation of apoptosis
and metastasis of tumor cells by modulating NF-jB activity has
been illustrated in several studies [32,33]. NF-jB is also a
redox-dependent transcription factor, whose activity is widely
regulated by ROS levels of the cells [34]. Contradicting the theory
that several anti-cancer drugs augment NF-jB activity through
ROS [35], there are studies where ROS negatively regulates NF-
jB [36]. However a clear-cut interaction among p53, ROS and
NF-jB in relation to metastasis remains undeﬁned. Here we re-
port that theaﬂavin-induced activation of p53–ROS–p38MAPK
loop in MCF-7 cells was responsible for NF-jB inhibition and sub-
sequent anti-migratory action of theaﬂavins (Fig. 5). A search for
the underlying mechanisms failed to show any direct association
between p-Ser15-p53 and NF-jB, instead, phosphorylated p53
interacted directly with IKKb thereby resulting in reduced IjBa-
phosphorylation. As a consequence, nuclear translocation of NF-
jB was inhibited [37]. These ﬁndings are supported by the previ-
ous reports that upon phosphorylation Wt-p53 directly interacted
with IKKb to inhibit its kinase activity that coincided with
reduced IjBa-phosphorylation [38]. NF-jB is known to stimulate
metastasis in breast and prostrate cancer by regulating the
expression of metastatic proteins like urokinase-type plasmino-
gen activator and MMPs [39,40]. On the other hand, suppression
of NF-jB inhibited MMP-2 and MMP-9 in various cancer cells
[41,42]. The present study, for the ﬁrst time, disclosed the pivotal
role of NF-jB in theaﬂavin-induced down-regulation of MMP-2
and MMP-9.
n conclusion, we have established that to inhibit breast can-
cer cell migration, theaﬂavins require the activation of the p53/
ROS/p38MAPK loop that leads to the ampliﬁcation of the signal
to inhibit NF-jB. Inhibition of NF-jB ﬁnally results in retarda-
tion of breast cancer cells migration by subsequently suppress-
ing MMP-2 and MMP-9. Overall, theaﬂavins may become the
valuable anti-invasive drug candidates for cancer therapy in
future.
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